Ovarian reserve is an estimate of the supply of primary follicles remaining in the ovary. Ovarian reserve diminishes with a woman's age, making it more difficult to get pregnant.
Assisted reproductive technologies involve an emotional and financial investment. It is helpful for patients deciding whether to participate in assisted reproductive technologies to better estimate their probability of success. Tests for ovarian reserve provide some information regarding how likely it is that a woman's ovaries will produce multiple follicles after hormone stimulation, which in turn is associated with the likelihood of having a baby.
AMH is a normal product of developing ovarian follicles. The amount of AMH measured in serum during the start of a new menstrual cycle is directly related to the number and health of small growing follicles.
AMH levels are low in women with diminished ovarian reserve. If your AMH level is below or at the low end of the normal menstrual cycle range, you have a lower chance of responding well to ovarian stimulation in assisted reproductive technology protocols than someone with a higher AMH level. A poor response means that your ovary will produce relatively few oocytes (eggs) after hormone stimulation and therefore you will have fewer embryos after fertilization and a lower chance of getting pregnant.
Yes. Serum FSH is an indirect measure of ovarian reserve. Several publications have shown that a combination of FSH and AMH measurement can better predict ovarian response and pregnancy outcome than FSH alone.
See your physician to have your blood drawn and send the blood sample to a laboratory offering the AMH test.
Your AMH result will be sent to your physician within two to four business days.
Since the AMH test is relatively new, it is not frequently covered by health insurance; however, it is best to speak directly to your physician or health insurance company